2.09
-0.03(-1.42%)
Currency In USD
| Previous Close | 2.12 |
| Open | 2.13 |
| Day High | 2.18 |
| Day Low | 2.09 |
| 52-Week High | 9.79 |
| 52-Week Low | 1.15 |
| Volume | 1.43M |
| Average Volume | 4.05M |
| Market Cap | 324.2M |
| PE | -3.03 |
| EPS | -0.69 |
| Moving Average 50 Days | 2.03 |
| Moving Average 200 Days | 3.69 |
| Change | -0.03 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $216.13 as of July 01, 2025 at a share price of $2.09. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $635.26 as of July 01, 2025 at a share price of $2.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
GlobeNewswire Inc.
Jun 09, 2025 12:00 PM GMT
Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary SessionDURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- H
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
AV Access Study to be Presented at the Vascular Annual Meeting (VAM25)DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason